Publicaciones en las que colabora con Fernando Jesús Antoñanzas Villar (41)

2023

  1. Does diagnostic testing always decrease antibiotics prescriptions?

    European Journal of Health Economics, Vol. 24, Núm. 5, pp. 673-678

  2. Tenders for generics and biosimilars: a challenging purchasing policy

    European Journal of Health Economics

2022

  1. Diagnostic testing for sepsis: A systematic review of economic evaluations

    Antibiotics, Vol. 11, Núm. 1

2021

  1. Efficiency of diagnostic testing for helicobacter pylori infections—a systematic review

    Antibiotics, Vol. 10, Núm. 1, pp. 1-11

  2. Using point-of-care diagnostic testing for improved antibiotic prescription: an economic model

    Health Economics Review, Vol. 11, Núm. 1

2019

  1. Implementation of risk-sharing contracts as perceived by Spanish hospital pharmacists

    Health Economics Review, Vol. 9, Núm. 1

  2. Incentivos antes de la autorización de medicamentos para promover la medicina personalizada: un análisis teórico

    XXXIX Jornadas de Economía de la Salud. La transparencia es saludable. La importancia de la rendición de cuentas en Sanidad

  3. Pre-approval incentives to promote adoption of personalized medicine: A theoretical approach

    Health Economics Review, Vol. 9, Núm. 1

  4. The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments

    PharmacoEconomics, Vol. 37, Núm. 12, pp. 1469-1483

2018

  1. Implantación de contratos de riesgo compartido en España y su vinculación hacia la medicina personalizada

    XXXVIII Jornadas de Economía de la Salud. Compartiendo decisiones: ¿Qué cambios se requieren?

  2. Personalized medicine and pay-for-performance: should pharmaceutical firms be fully penalized when treatment fails?

    PharmacoEconomics

2017

  1. EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data?

    European Journal of Health Economics, pp. 1-3

  2. Endogenous versus exogenous generic reference pricing for pharmaceuticals

    International Journal of Health Economics and Management, Vol. 4, Núm. 4, pp. 413-432

  3. MEDICINA PERSONALIZADA Y PAGOS POR RESULTADOS: ¿SE DEBE PENALIZAR SI NO HAY RESULTADOS?

    XXXVII Jornadas de economía de la Salud. Ciencia para la Acción

2016

  1. Implementing personalized medicine with asymmetric information on prevalence rates

    Health Economics Review, Vol. 6, Núm. 1, pp. 1-8

  2. Improving health care systems by building 'more Europe'

    European Journal of Health Economics, Vol. 17, Núm. 7, pp. 787-789

2015

  1. Efficient health research and improving Europeans' health

    European Journal of Health Economics, Vol. 16, Núm. 9, pp. 913-915

  2. Is personalized medicine a panacea for health management? Some thoughts on its desirability

    European Journal of Health Economics, Vol. 16, Núm. 5, pp. 455-457

  3. Some economics on personalized and predictive medicine on personalized and predictive medicine

    European Journal of Health Economics, Vol. 16, Núm. 9, pp. 985-994

2014

  1. Impacto Delrealdecreto-Ley 16/2012 Sobre Elcopago Farmaceutico En Elnúmero De Recetas Y En Elgasto Farmacéutico

    Revista Espanola de Salud Publica, Vol. 88, Núm. 2, pp. 233-249